Insmed (NASDAQ:INSM) Coverage Initiated at Wells Fargo & Company

Key Points

• Wells Fargo & Company has initiated coverage on Insmed (NASDAQ: INSM) with an "overweight" rating and a price target of $171.00, indicating a potential upside of 3.16% from its current stock price.
• Nineteen analysts have rated Insmed with a Buy, while the consensus price target stands at $152.88, showing strong confidence in its stock performance.
• In the latest quarter, Insmed reported a revenue of $107.42 million, exceeding analysts' expectations, but reported a loss of ($1.70) EPS, which was below the consensus estimate of ($1.30).

Equities research analysts at Wells Fargo & Company began coverage on shares of Insmed (NASDAQ:INSM - Get Free Report) in a research note issued on Monday,Briefing.com Automated Import reports. The firm set an "overweight" rating and a $171.00 price target on the biopharmaceutical company's stock. Wells Fargo & Company's price objective would indicate a potential upside of 3.16% from the company's current price.

Other research analysts have also issued research reports about the company. JPMorgan Chase & Co. increased their price objective on Insmed from $111.00 to $135.00 and gave the company an "overweight" rating in a report on Wednesday, August 20th. Mizuho lifted their target price on shares of Insmed from $130.00 to $165.00 and gave the stock an "outperform" rating in a report on Wednesday, August 13th. Jefferies Financial Group upped their price target on shares of Insmed from $129.00 to $148.00 and gave the company a "buy" rating in a report on Wednesday, August 13th. Truist Financial boosted their price objective on Insmed from $126.00 to $139.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. Finally, Guggenheim raised their target price on Insmed from $125.00 to $172.00 and gave the company a "buy" rating in a report on Monday, September 8th. Nineteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $152.88.

Insmed Stock Performance

Shares of INSM opened at $165.76 on Monday. The firm has a market cap of $35.04 billion, a price-to-earnings ratio of -29.03 and a beta of 1.03. The company's fifty day moving average is $143.38 and its 200-day moving average is $105.27. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. Insmed has a 12 month low of $60.40 and a 12 month high of $166.44.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The business had revenue of $107.42 million during the quarter, compared to the consensus estimate of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The company's revenue for the quarter was up 18.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. Equities analysts expect that Insmed will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the company's stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $145.45, for a total value of $11,129,834.00. Following the sale, the insider directly owned 36,461 shares in the company, valued at approximately $5,303,252.45. This represents a 67.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Melvin Md Sharoky sold 10,000 shares of the stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $145.39, for a total value of $1,453,900.00. Following the completion of the transaction, the director directly owned 262,675 shares of the company's stock, valued at approximately $38,190,318.25. The trade was a 3.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 152,657 shares of company stock worth $21,442,198. Insiders own 3.00% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in Insmed by 0.3% during the first quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company's stock worth $1,393,675,000 after buying an additional 49,149 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Insmed by 1.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company's stock valued at $985,938,000 after buying an additional 219,131 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its position in Insmed by 109.2% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company's stock worth $262,967,000 after buying an additional 1,799,382 shares in the last quarter. Artisan Partners Limited Partnership grew its holdings in Insmed by 3.0% during the 2nd quarter. Artisan Partners Limited Partnership now owns 3,314,341 shares of the biopharmaceutical company's stock worth $333,555,000 after acquiring an additional 97,073 shares during the last quarter. Finally, Alliancebernstein L.P. increased its position in Insmed by 2.5% in the 1st quarter. Alliancebernstein L.P. now owns 2,423,513 shares of the biopharmaceutical company's stock valued at $184,890,000 after acquiring an additional 59,952 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.